Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-11-25T09:06:06.890Z Has data issue: false hasContentIssue false
  • English
  • Français

Pramipexole: Augmentation in the Treatment of Depressive Symptoms

Published online by Cambridge University Press:  07 November 2014

Sanjay Gupta ,
Jennifer L. Vincent  and
Bradford Frank
Get access Rights & Permissions [Opens in a new window]

Abstract

We describe a retrospective case series of three patients, two with bipolar depression and one with unipolar depression. Pramipexole is a Food and Drug Administration-approved antiparkinsonian agent, which, when used to augment antidepressants, would be considered an off-label use and should be discussed with the patient. These patients had robust responses to pramipexole augmentation of their treatment regimen. All three patients had been taking an atypical antipsychotic. The depressive symptoms were evaluated using the Hamilton Rating Scale for Depression.

Type
Case Report
Information
CNS Spectrums , Volume 11 , Issue 3 , March 2006 , pp. 172 - 175
Copyright
Copyright © Cambridge University Press 2006

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Calabrese, JR, Hirshfield, RM, Reed, M, et al.Impact of bipolar disorder on a US community sample. J Clin. Psychiatry. 2003;64:425–432.Google Scholar
2.Keck, PE Jr, Mc Elroy, SL, Arnold, SL. Bipolar disorder. Med Clin North Am. 2001;85:645–661.Google Scholar
3.Judd, LL, Schettler, PJ, Akiskal, HS, et al.Long-term symptomatic status of bipolar I vs. bipolar II disorders. Int J Neuropsychopharmacol. 2003;6:127–137.Google Scholar
4.Rihmer, Z, Pestality, P. Bipolar II disorder and suicidal behavior. Psychiatr Clin North Am. 1999;22:667–673.Google Scholar
5.Keck, PE Jr, Nelson, EB, McElroy, SL. Advances in pharmacologic treatment of bipolar depression. Biol Psychiatry. 2003;53:671–679.Google Scholar
6.Muzina, DJ, Calabrese, JR. Recent placebo-controlled acute trials in bipolar depression: focus on methodology. Int J Neuropsychopharmacol. 2003;6:285–291.Google Scholar
7.Yatham, LN, Calabrese, JR, Kusumakar, V. Bipolar depression: criteria for treatment selection, definition of refractoriness and treatment options. Bipolar Disord. 2003;5:85–97.Google Scholar
8.Arndt, J, Hyttel, J, Overo, KF. Prolonged treatment with the specific 5-HT inhibitor citalopram: effect on dopaminergic and serotonergic functions. Pol J Pharmacol Pharm. 1984;36:221–230.Google Scholar
9.D'Aquila, PS, Collu, M, Gessa, GL, Serra, G. The role of dopamine in the mechanism of action of antidepressant drugs. Eur J Pharmacol. 2000;405:365–373.Google Scholar
10.Maj, J, Rogoz, Z. Pharmacological effects of venlafaxine a new antidepressant, given repeatedly, on the alpha 1-adrenergic, dopamine, and serotonin systems. J Neural Transm. 1999;106:197–211.Google Scholar
11.Willner, P. The mesolimbic dopamine system as a target for rapid antidepressant action. Int Clin Psychopharmacol. 1997;12(suppl 3):S7–S14.Google Scholar
12.Nierenberg, AA, Dougherty, D, Rosenbaum, JF. Dopaminergic agents and stimulants as antidepressants as antidepressant augmentation strategies. J Clin Psychiatry. 1998;59(suppl 5):60–63.Google Scholar
13.Black, KJ, Hershey, T, Koller, JM, et al.A possible substrate for dopamine-related changes in mood and behavior: prefrontal and limbic effects of D3-preferring dopamine agonist. Proc Natl Acad Sci USA. 1999;17113–17118.Google Scholar
14.Drevets, WC. Neuroimaging and neuropathological studies of depression: implications for the cognitive-emotions features of mood disorders. Curr Opin Neurobiol. 2001;11:240–249.Google Scholar
15.Carvey, PM, McGuire, SO, Ling, ZT. Neuroprotective effects of D3 dopamine receptor agonists. Parkinsonism Helat Disord. 2001;7:213–223.CrossRefGoogle ScholarPubMed
16.Zarate, CA Jr, Payne, JL, Singh, J, et al.Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry. 2004;56:54–60.Google Scholar
17.DeBattista, C, Solvanson, HB, Breen, JA, Schatzberg, AF. Pramipexole augmentation of a selective serotonin reuptake inhibitor in the treatment of depression. J Clin Psychopharmacol. 2000;20:274–275.Google Scholar
18.Goldberg, JF, Frye, MA, Dunn, RT. Pramipexole in refractory bipolar depression. Am J Psychiatry. 1999;156:798.Google Scholar
19.Goldberg, JF, Burdick, KE, Endick, CJ. Preliminary randomized double-blind placebo controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry. 2004;161:564–566.Google Scholar
20.Piercey, MF. Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease. Clin Neuropharmacol. 1998;21:141–151.Google Scholar
21.Le, WD, Jankowic, J. Are dopamine receptor agonists neuroprotective in Parkinson's disease? Drugs Aging. 2001;18:389–396.Google Scholar
22.Pramipexole hydrochloride [package insert]. Ridgefield, Conn: Boehringer Ingelheim Pharmaceuticals, Inc; 2005.Google Scholar
23.Perugi, G, Toni, C, Ruffolo, G, Frare, F, Akiskal, H. Adjunctive dopamine agonists in treatment resistant bipolar II depression: an open case series. Pharmacopsychiatry. 2001;34:137–141.Google Scholar